Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brimonidine + dorzolamide
- Development stage
- Unknown
- Lead developer
- Laboratorios Sophia
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Brimonidine + dorzolamide is an ophthalmic fixed-combination of two small-molecule intraocular pressure–lowering agents used in the management of open-angle glaucoma and ocular hypertension. Brimonidine is a selective alpha-2 adrenergic receptor agonist that decreases aqueous humor production and increases uveoscleral outflow, while dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by blocking carbonic anhydrase II in the ciliary processes.[2][4][8] By combining these complementary mechanisms in a single topical formulation, the product provides additive intraocular pressure reduction compared with either component alone and can improve adherence relative to separate eye drops in patients requiring multi-drug therapy.[3][6][7]
- Brand names
- Kukje Dorzolamide Brimonidine Eye Drops
- Other names
- dorzolamide + brimonidinebrimonidine tartrate + dorzolamide hydrochloride
02
Targets
ADRA2A (α2A)CA2 (Carbonic Anhydrase 2)
Beyond the preview
Go deeper on brimonidine + dorzolamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brimonidine + dorzolamide.